News

Iredell Free News

Iredell Free News examines MOD GRF 1-29, a growth hormone-releasing peptide with four amino acid modifications. The article reports that it is not FDA-approved and lacks large, long-term trials establishing safety or effectiveness; most published human evidence concerns the distinct, longer-acting CJC-1295 with DAC.

Vademecum

A scoping review summarized by Vademecum examined six compounds marketed for musculoskeletal recovery and performance, finding that 67% of identified publications used animal models. Researchers reported that claimed benefits remain unsubstantiated by current human trials, with limited study quality and documented cardiovascular and metabolic risks.

Boxing Insider

Boxing Insider reports that HHS announced an interim enforcement discretion policy covering six peptides for compounding pharmacies. The article says the change does not alter restrictions for licensed fighters and notes limited human clinical evidence for some compounds.

Men's Fitness

Men’s Fitness reports that WADA’s rules taking effect in January 2027 explicitly identify unapproved research peptides as prohibited, clarifying existing restrictions. The article says semaglutide and tirzepatide remain permitted but have been added to WADA’s 2027 monitoring program.

Yahoo News Singapore

A Reader’s Digest article carried by Yahoo News Singapore examines growing interest in wellness peptides, contrasting personal testimonials with limited human evidence and safety concerns. It also reports that Health and Human Services Secretary Robert F. Kennedy Jr. announced plans to ease restrictions on 14 peptides.

PubMed: BPC-157

A narrative review found limited human evidence for BPC-157, thymosin beta-4, and TB-500 in musculoskeletal recovery. The authors reported that BPC-157’s human musculoskeletal evidence consists of one small uncontrolled retrospective case series, and none of the agents has controlled human orthopaedic efficacy evidence or an FDA-approved musculoskeletal indication.